Prevention of stroke, cognitive impairment and dementia in patients with hypertension during the provision of primary health care

Cover Page

Cite item

Full Text

Abstract

The article deals with questions of prevention of stroke and cognitive impairment in hypertensive patients at the stage of primary health care. The data of the study Syst-Eur (The Systolic Hypertension in Europe) clearly demonstrate the effectiveness of the dihydropyridine calcium antagonist nitrendipine in reducing the risk of stroke, cognitive impairment and dementia in patients with hypertension. The emergence of the Russian pharmaceutical market, the drug nitrendipine - Nitremed - makes it possible to optimize the prevention of cerebrovascular disease and cognitive impairment in hypertensive patients.

About the authors

D. I Trukhan

Omsk State Medical University of the Ministry of Health of the Russian Federation

Email: dmitry_trukhan@mail.ru
д-р мед. наук, доц., проф. каф. внутренних болезней и поликлинической терапии ФГБОУ ВО ОмГМУ 644099, Russian Federation, Omsk, ul. Lenina, 12

E. L Davydov

V.F.Voino-Yasenetsky Krasnoyarsk State Medical University of the Ministry of Health of the Russian Federation

Email: devgenii@bk.ru
д-р мед. наук, доц. каф. пропедевтики внутренних болезней и терапии ФГБОУ ВО «КрасГМУ им. проф. В.Ф.Войно-Ясенецкого» 660022, Russian Federation, Krasnoyarsk, ul. Partizana Zhelezniaka, d. 1

References

  1. Warlow C, Sudlow C, Dennis M et al. Stroke. Lancet 2003; 362 (9391): 1211-24.
  2. Swerdel J.N, Rhoads G.G, Cheng J.Q et al. Myocardial Infarction Data Acquisition System (MIDAS 29) Study Group. Ischemic Stroke Rate Increases in Young Adults: Evidence for a Generational Effect? J Am Heart Assoc 2016; 5 (12).
  3. Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. http://circ.ahajournals.org/content/early/2017/01/25/CIR.0000000000000485
  4. Захаров В.В., Яхно Н.Н. Когнитивные расстройства в пожилом и старческом возрасте: Методическое пособие для врачей. М., 2005.
  5. Яхно Н.Н. Когнитивные расстройства в неврологической клинике. Неврологический журн. 2006; 11 (Прил. 1): 4-12.
  6. Захаров В.В. Принципы ведения пациентов с когнитивными нарушениями без деменции. Рус. мед. журн. 2008; 12: 1645-9.
  7. Di Carlo A, Baldereschi M, Amaducci L et al. Cognitive impairment without dementia in older people: prevalence, vascular risk factors, impact on disability. The Italian Longitudinal Study on Aging. J Am Ger Soc 2000; 48: 775-82.
  8. Захаров В.В., Яхно Н.Н. Нарушения памяти. М.: ГЭОТАР-Мед., 2003.
  9. Apostolo J, Holland C, O'Connell M.D et al. Mild cognitive decline. A position statement of the Cognitive Decline Group of the European Innovation Partnership for Active and Healthy Ageing (EIPAHA). Maturitas 2016; 83: 83-93.
  10. Graham J.E, Rockwood K, Beattie E.L et al. Prevalence and severity of cognitive impairment with and without dementia in an elderly population. Lancet 1997; 349: 1793-6.
  11. Захаров В.В., Вахнина Н.В. Когнитивные нарушения при цереброваскулярных заболеваниях. Эффективная фармакотерапия. 2014; 1: 14-21.
  12. Srikanth V.K, Thrift A.G, Saling M.M et al. Increased risk of cognitive impairment 3 months after mild to moderate first - ever stroke: a Community - Based Prospective Study of Nonaphasic English - Speaking Survivors. Stroke 2003; 34 (5): 1136-43. Epub 2003 Apr 17.
  13. Rasquin S.M, Verhey F.R, van Oostenbrugge R.J et al. Demographic and CT scan features related to cognitive impairment in the first year after stroke. J Neurol Neurosurg Psychiatry 2004; 75 (11): 1562-7.
  14. Sachdev P.S, Brodaty H, Valenzuela M.J et al. Clinical determinants of dementia and mild cognitive impairment following ischaemic stroke: the Sydney Stroke Study. Dement Geriatr Cogn Disord 2006; 21 (5-6): 275-83. Epub 2006 Feb 10.
  15. Ihle-Hansen H, Thommessen B, Wyller T.B et al. Incidence and subtypes of MCI and dementia 1 year after first - ever stroke in patients without pre - existing cognitive impairment. Dement Geriatr Cogn Disord 2011;32(6):401-7. doi: 10.1159/000335361. Epub 2012 Feb 3.
  16. Захаров В.В., Вахнина Н.В. Инсульт и когнитивные нарушения. Неврология, нейропсихиатрия, психосоматика. 2011; 3 (2): 8-16
  17. Парфенов В.А., Хасанова Д.Р. Ишемический инсульт. М.: МИА, 2012.
  18. Lisabeth L.D, Sanchez B.N, Baek J et al. Neurological, functional, and cognitive stroke outcomes in Mexican Americans. Stroke 2014; 45 (4): 1096-101.
  19. Ivan C.S, Seshadri S, Beiser A et al. Dementia after stroke: the Framingham Study. Stroke 2004; 35 (6): 1264-8. Epub 2004 Apr 29.
  20. Srikanth V.K, Anderson J.F, Donnan G.A et al. Progressive dementia after first - ever stroke: a community - based follow - up study. Neurology 2004; 63 (5): 785-2.
  21. Pendlebury S.T, Rothwell P.M. Prevalence, incidence, and factors associated with prestroke and post - stroke dementia: a systematic review and meta - analysis. Lancet Neurol 2009; 8 (11): 1006-18.
  22. Захаров В.В., Вахнина Н.В. Особенности ведения пациентов с постинсультными когнитивными нарушениями. Атмосфера. Нервные болезни. 2011; 3: 14-20.
  23. Вахнина Н.В. Профилактика и лечение постинсультных когнитивных нарушений. Эффективная фармакотерапия. 2014; 42 (4): 32-9.
  24. Захаров В.В., Вахнина Н.В., Громова Д.О., Тараповская А.А. Диагностика и лечение когнитивных нарушений после инсульта. Мед. совет. 2015; 10: 14-21
  25. Преображенская И.С., Науменко А.А. Патогенез, диагностика и терапия болезни Альцгеймера. Мед. совет. 2015; 5: 46-54.
  26. Котов А.С., Елисеев Ю.В., Семенова Е.И. Болезнь Альцгеймера: от теории к практике. Мед. совет. 2015; 18: 41-4.
  27. Рекомендации Европейского Общества по АГ. 2013 год. URL: http://gipertonik.ru/recommendation-european-society.
  28. Poole-Wilson P.A, Lubsen J, Kirwan B.A et al. On behalf of the ACTION (A Coronary disease Trial Investigating Outcome with Nifedipine gastrointestinal therapeutic system) investigators. Effect of long - acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet 2004; 364: 849-57.
  29. Staessen J.A, Fagard R, Thijs L et al. Randomised double - blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997; 350 (9080): 757-64.
  30. Forette F, Seux M.L, Staessen J.A et al. Systolic Hypertension in Europe Investigators. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst - Eur) study. Arch Intern Med 2002; 162 (18): 2046-52.
  31. Dahlot B, Devereux R.D, Kjeldsen S.E et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003.
  32. Lithell H, Hansson L, Skoog I et al. SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double - blind intervention trial. J Hypertens 2003; 21: 875-86.
  33. PATS Collaborating Group. Post - stroke antihypertensive treatment study: preliminary results. Clin Med J 1995; 108: 710-7.
  34. PROGRESS Collaborative Group. Randomised trial of perindopril - based blood - pressure - lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033-41.
  35. Sever P.S, Dahlof B, Poulter N.R et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower - than - average cholesterol concentrations, in the Anglo - Scandinavian cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): A multicentre randomized controlled trial. Lancet 2003; 361: 1149-58.
  36. Tuomilehto J, Rastenyte D, Birkenhager W.H et al. Effects of calcium - channel blockade in older patients with diabetes and systolic hypertension: Systolic Hypertension in Europe Trial Investigators. N Engl J Med 1999; 340: 677-84.
  37. Wang J.G, Staessen J.A, Gong L, Liu L. Chinese trial on isolated systolic hypertension in the elderly. Systolic Hypertension in China (Syst - China) Collaborative Group. Arch Intern Med 2000; 160 (2): 211-20.
  38. Bufalino V.J, Masoudi F.A, Stranne S.K et al. The American Heart Association's recommendations for expanding the applications of existing and future clinical registries: a policy statement from the American Heart Association. Circulation 2011; 123 (19): 2167-79.
  39. Трухан Д.И., Мазуров А.Л. Легкие и умеренные когнитивные нарушения: актуальные вопросы диагностики и лечения на этапе оказания первичной медико - санитарной помощи // Consilium Medicum. 2016; 18 (2): 74-80.
  40. Захаров В.В. Диагностика и лечение когнитивных нарушений // Неврология и ревматология. Приложение к журналу Consilium Medicum. 2014; 1: 21-7.
  41. Dlugaj M, Winkler A, Weimar C et al. Anemia and Mild Cognitive Impairment in the German General Population. J Alzheimers Dis 2015; 49 (4): 1031-42.
  42. Papachristou E, Ramsay S.E, Papacosta O et al. The Test Your Memory cognitive screening tool: sociodemographic and cardiometabolic risk correlates in a population - based study of older British men. Int J Geriatr Psychiatry 2015 Oct 21.
  43. Knopman D.S, Beiser A, Machulda M.M et al. Spectrum of cognition short of dementia: Framingham Heart Study and Mayo Clinic Study of Aging. Neurology. 2015; 85 (19): 1712-21.
  44. Lehert P, Villaseca P, Hogervorst E et al. Individually modifiable risk factors to ameliorate cognitive aging: a systematic review and meta - analysis. Climacteric 2015; 18 (5): 678-89.
  45. Booker A, Jacob L.E, Rapp M et al. Risk factors for dementia diagnosis in German primary care practices. Int Psychogeriatr 2016 Jan 8; 1-7.
  46. van Rooij F.G, Kessels R.P, Richard E et al. Cognitive Impairment in Transient Ischemic Attack Patients: A Systematic Review. Cerebrovasc Dis 2016; 42 (1-2): 1-9.
  47. Tzivian L, Dlugaj M, Winkler A et al. Long - Term Air Pollution and Traffic Noise Exposures and Mild Cognitive Impairment in Older Adults: A Cross - Sectional Analysis of the Heinz Nixdorf Recall Study. Environ Health Perspect 2016 Feb 5.
  48. Захаров В.В., Дроздова Е.А. Когнитивные нарушения у больных с черепно - мозговой травмой. Неврология, нейропсихиатрия, психосоматика. 2013; 4: 88-93.
  49. Захаров В.В., Вахнина Н.В. Когнитивные нарушения при депрессии. Эффективная фармакотерапия. 2015; 1: 18-26.
  50. Строков И.А., Захаров В.В., Строков К.И. Диабетическая энцефалопатия. Современное состояние проблемы. Доктор.Ру. 2013; 7-2: 29-35.
  51. Куимов А.Д., Голубкова М.Е. Коррекция когнитивных нарушений у больных с сердечно - сосудистыми заболеваниями // Неврология и ревматология. Приложение к журналу Consilium Medicum. 2012; 2: 49-51.
  52. Чухловина М.Л. Неврологические осложнения сердечно - сосудистых заболеваний // Справочник поликлинического врача. 2012; 8: 51-53.
  53. Захаров В.В., Вахнина Н.В., Остроумова О.Д. Коррекция когнитивных нарушений у пациента с артериальной гипертензией и сердечной недостаточностью: как сделать правильный выбор. Эффективная фармакотерапия. 2014; 12: 12-8.
  54. Forette F, Seux M.L, Staessen J.A. Prevention of dementia in randomised double - blind placebo - controlled Systolic Hypertension in Europe trial. Lancet 1998; 352: 1347-51.
  55. Parneti L, Senin U, Mecocci P. Cognitive enhancement therapy for Alzheimer's disease: the way forward. Drugs 1997; 53: 752-68.
  56. Mason R.P, Leeds P.R, Jacob P.F et al. Inhibition of excessive neuronal apoptosis by the calcium antagonist amlodipine and antioxidants in cerebellar granule cells. J Neurochem 1999; 72: 1448-56.
  57. Thibault O, Porter N.M, Chen K.C. Calcium Dysregulation in neuronal aging and Alzheimer's disease: hystory and new directions. Cell Calcium 1998; 25: 417-33.
  58. Zipfel G.J, Lee J.M, Choi D.W. Reducing calcium overload in the ischemic brain. N Engl J Med 1999; 341: 1543-4.
  59. Poscale A, Etchoberrigaray R. Calcium alterations in Alzheimer's disease: pathophysiology, models and therapeutic opportunities. Pharmacol Res 1999; 39: 81-8.
  60. Lublin A.L, Gandy S. Amyloid - beta oligomers: possible roles as key neurotoxins in Alzheimer’s Disease. Mt Sinai J Med 2010; 77: 43-9.
  61. Hong Y.L. The relationship between calcium antagonist - induced hypotension and central monoaminergic system in spontaneously hypertensive rats. Int J Clin Pharmacol Ther Toxicol 1987; 11: 589-97.
  62. Murzenok P.P, Huang B.S, Leenen F.H.H. Sympathoinhibition by central and periferal infusion of nifedipine in spontaneously hypertensive rats. Hypertension 2000; 35: 631-6.
  63. Bell R.D, Zlokovic B.V. Neurovascular mechanisms and blood - brain barrier disorder in Alzheimer’s disease. Acta Neuropathol 2009; 118: 103-13.
  64. Deane R, Bell R.D, Sagare A, Zlokovic B.V. Clearance of amyloid - beta peptide across the blood - brain barrier: implication for therapies in Alzheimer’s disease. CNS Neurol Disord Drug Targets 2009; 8: 16-30.
  65. Gould R.J, Murphy K.M.M, Snyder S.H. Autoradiographic localization of calcium channel antagonist receptors in rats brain with [3H] nitrendipine. Brain Res 1985; 330: 217-33.
  66. Paris D, Bachmeier C, Patel N et al. Selective antihypertensive dihydropyridines lower Ab accumulation by targeting both the production and the clearance of Ab across the blood - brain barrier. Mol Med 2011; 17 (3-4): 149-62.
  67. Hanon O, Forette F. Prevention of dementia: lessons from SYST-EUR and PROGRESS. J Neurol Sci 2004; 226: 71-4.
  68. Yasar S, Corrada M, Brookmeyer R, Kawas C. Calcium channel blockers and risk of AD: the Baltimore Longitudinal Study of Aging. Neurobiol Aging 2005; 26: 157-63.
  69. Duron E, Hanon O. Antihypertensive treatments, cognitive decline, and dementia. J Alzheimers Dis 2010; 20: 903-14.
  70. Spinar J, Vitovec J. AII antagonists in the treatment of hypertension and prevention of CVA. Vnitr Lek 2013; 59 (1): 71-8.
  71. Coca A. Hypertension and vascular dementia in the elderly: the potential role of anti - hypertensive agents. Curr Med Res Opin 2013; 29 (9): 1045-54.
  72. Godfraind T. Calcium channel blockers in cardiovascular pharmacotherapy. J Cardiovasc Pharmacol Ther 2014; 19 (6): 501-15.
  73. Peters J, Booth A, Peters R. Potential for specific dihydropyridine calcium channel blockers to have a positive impact on cognitive function in humans: a systematic review. Ther Adv Chronic Dis 2015; 6 (4): 160-9.
  74. Остроумова О.Д. Профилактика инсульта и деменции у больных высокого риска // Consilium Medicum. 2015; 17 (10): 73-6.
  75. Чурсина Т.Я., Михалев К.А. «Фармакологический лабиринт», или Поиски оптимальной комбинации. Артериальная гипертензия. 2012; 5: 32-8.
  76. Корж А.Н., Говбах И.А. Рациональная комбинированная терапия артериальной гипертензии: оптимизация профилактики цереброваскулярных нарушений. Артериальная гипертензия. 2013; 5: 9-15.
  77. Крючкова О.Н., Ицкова Е.А., Лутай Ю.А., Турна Э.Ю. Новые горизонты фиксированной антигипертензивной терапии. Крымский терапевтический журн. 2015; 17 (2): 41-8.
  78. Энанорм (Enanorm). Инструкция по применению, противопоказания, состав и цена. URL: http://www.rlsnet.ru/tn_index_id_49497.htm / Enanorm (Enanorm). Instruktsiia po primeneniiu, protivopokazaniia, sostav i tsena. URL: http://www.rlsnet.ru/tn_index_id_49497.htm [in Russian]
  79. Трухан Д.И., Поздняков Ю.М. Актуальные аспекты рациональной фармакотерапии в кардиологии. Плюсы и минусы фиксированных и произвольных комбинаций антигипертензивных препаратов // Consilium Medicum. 2016; 18 (1): 25-31.
  80. Трухан Д.И., Поздняков Ю.М. Лечение артериальной гипертензии проблемы реальной клинической практики // Справочник поликлинического врача. 2016; 3: 4-8.

Copyright (c) 2017 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies